Home › Upcoming votes › CHINA PHARMA HOLDINGS, INC.
No fund votes on record from prior seasons.
Read the proxy statement on EDGAR
Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.
Annual meeting: election of three independent directors, authority for a reverse stock split at a ratio of up to 1:50, and Amendment No.4 to the 2010 Long-Term Incentive Plan.
“has approved, on October 20, 2026, the Amendment No.4 (the "Amendment") to the Amended and Restated Long-Term 2010 Incentive Plan (the "Plan") to increase the number of shares of the Common Stock, that are reserved thereunder by 8,034,200 shares from 569,600 shares to 8,603,800 shares.” Find it in the filing
“To consider and approve the Company to effect a reverse stock split, at a ratio of up to 1:50 (the "RS Ratio Range"), as the final applicable ratio and effective time to be determined by the Board” Find it in the filing
“if the Board effects the Reverse Stock Split at a ratio greater than 1-for-20 before April 15, 2027, the cumulative ratio of the Company's reverse stock splits over the prior two-year period, together with the 1-for-10 reverse stock split effected on April 15, 2025, would be 200 shares or more to one.” Find it in the filing
“To consider and approve an amendment to the Articles of Incorporation of the Company to effect a reverse stock split, as needed, at a ratio of up to 1:50, such that every holder of common stock, par value $0.001 per share, of the Company (the "Common Stock") shall receive one share of Common Stock for pro rata twenty shares of Common Stock held” Find it in the filing
“As of the Record Date, we had issued shares of restricted stock or stock options to purchase shares of common stock in an aggregate of approximately 9,800 shares and approximately 559,800 shares of Common Stock were available for issuance under the Plan. There were 4 participants on the Plan as of the Record Date.” Find it in the filing
“As of the Record Date, we have issued and outstanding 43,022,002 shares of Common Stock.” Find it in the filing
“Except that our directors and executive officers are eligible to receive awards under the Amended and Restated 2010 Long-Term Incentive Plan, the share reserve of which would be increased by Proposal No. 3” Find it in the filing
“Future awards under the Plan will be granted at the discretion of the Compensation Committee, and, therefore, the types, numbers, recipients, and other terms of such awards cannot be determined at this time. No awards have been granted that are contingent on the approval of the Amendment.” Find it in the filing
“To consider and approve the Company to effect a reverse stock split, at a ratio of up to 1:50 (the "RS Ratio Range")” Find it in the filing
Last year’s proxy statement, page 12: “Company to effect a reverse stock split, at a ratio of up to 1:20 (the "RS Ratio Range")”
“To consider and approve the Company to effect a reverse stock split, as needed, at a ratio of up to 1:50” Find it in the filing
Last year’s proxy statement, page 3: “To consider and approve an amendment to the Articles of Incorporation of the Company to effect a reverse stock split, as needed, at a ratio of up to 1:20”
“On October 23, 2025, the Board of Directors approved the Amendment No.3 to the Amended and Restated Long Term 2010 Incentive Plan to increase the number of shares of Common Stock that are reserved thereunder by an additional 500,000 shares from 69,600 shares to 569,600 shares.” Find it in the filing
Ballot read from the proxy statement and checked. As listed in CHINA PHARMA HOLDINGS, INC.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | ELECTION OF INDEPENDENT DIRECTORS Director election |
Board | For | 3 nominees; support 99.9% to 99.9% |
| 2 | AUTHORIZE THE BOARD OF DIRECTORS TO EFFECT A REVERSE STOCK SPLIT | Board | For | — |
| 3 | APPROVAL OF THE AMENDMENT NO.4 TO THE AMENDED AND RESTATED 2010 LONG-TERM INCENTIVE PLAN | Board | For | — |
From CHINA PHARMA HOLDINGS, INC.’s Form 8-K, filed January 6, 2026, for the meeting held December 30, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Gene Michael Bennett | 99.9% | — |
| Elect Director: Yingwen Zhang | 99.9% | Elected |
| Elect Director: Baowen Dong | 99.9% | Elected |
| 2. A proposal to amend the Company's Articles of Incorporation to effect a reverse stock split, as needed, at a ratio up to 1:20, such that | 99.9% | Approved |
| 3. A proposal to adopt the Amendment No.3 to the Company's Amended and Restated 2010 Long-Term Incentive Plan | 99.9% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.